De Novo device
The Cooral System
Braincool AB · Intraoral Cooling Device (QUA, Class II) · First FDA decision Oct 14, 2022, newest Oct 14, 2022
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
2
Naming "Cooral"
MAUDE reports
0
Brand "Cooral", since 2015
PubMed studies
12
Mentioning "Cooral"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing The Cooral System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Cooral", any status and sponsor, newest update first.
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT04915599 · 10 participants · Start Jun 22, 2021 · Primary completion Apr 4, 2022
Device: Cooral® mouth cooling device (MCD) · For: Oral Mucositis
Sites: Basel, Switzerland
- Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized StudyPivotal-lookingCompleted
Uppsala UniversityAcademic, hospital or other
NCT03203733 · 182 participants · Start Jun 12, 2017 · Primary completion Dec 6, 2019
Device: Cooral™ · For: Cryotherapy Effect
Sites: Oslo, Norway; Linköping, Sweden; Örebro, Sweden · 5 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cooral", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QUA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cooral"[tiab]. The summary above synthesizes these.
- Protocol for a randomised controlled trial to study cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation.
Walladbegi J, Svanberg A, Gellerstedt M · BMJ Open · 2018Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism.
Raish M, Ahmad A, Shahid M, et al. · Molecules · 2023
- Feasibility and patient reported tolerance of cryotherapy with Cooral mouth cooling device in patients undergoing radiation therapy (CooRay): a pilot study.
Bunea A, Damian T, Bunea H, et al. · Transl Cancer Res · 2025
- Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS.
Zhou Y, Wang S, Ding T, et al. · Drug Dev Ind Pharm · 2015Research Support, Non-U.S. Gov't
- Protective effect of Echinacea purpurea (Immulant) against cisplatin-induced immunotoxicity in rats.
Khalaf AA, Hussein S, Tohamy AF, et al. · Daru · 2019
- Multidrug resistance-associated protein 2 (MRP2) is an efflux transporter of EGCG and its metabolites in the human small intestine.
Kikuchi T, Hayashi A, Ikeda N, et al. · J Nutr Biochem · 2022
- Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
Yang X, Zhang Q, Chen M, et al. · Xenobiotica · 2014
- Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization.
VanCott JL, Kobayashi T, Yamamoto M, et al. · Vaccine · 1996Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat.
Carlos MA, Du Souich P, Carlos R, et al. · J Pharm Sci · 2002Comparative Study, Research Support, Non-U.S. Gov't
- Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli lipopolysaccharide.
Terato K, Ye XJ, Miyahara H, et al. · Br J Rheumatol · 1996Research Support, Non-U.S. Gov't
- [Co-oral contraceptive pills with women protection post abortion].
Fan GS · Zhonghua Yi Xue Za Zhi · 2012
- [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T, Shimamoto Y, Kato T, et al. · Gan To Kagaku Ryoho · 1998English Abstract, Review
Other devices of this type
Also filed under product code QUA.
- Chemo MouthpieceChemo Mouthpiece, LLC · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.